Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.5% year on year to $240.7 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its non-GAAP loss of $0.48 per share was 22.4% below analysts’ consensus estimates.

Is now the time to buy TNDM? Find out in our full research report (it’s free).

StockStory’s Take

Tandem Diabetes Care’s second quarter results were met with a significant negative market reaction, reflecting investor concerns despite the company’s revenue surpassing Wall Street expectations. Management attributed the quarter’s performance to rising pump and supply volumes, higher average selling prices through channel management, and double-digit growth in renewals. CEO John Sheridan acknowledged that while U.S. pump shipments and customer retention remained strong, continued investments in business transformation and competitive pressures impacted operating margins, stating that “some of the adjustments to the U.S. numbers really acknowledge that a number of these initiatives are still in process, and that has delayed some of the benefit.”

Looking ahead, Tandem Diabetes Care’s guidance is shaped by ongoing investments in pharmacy channel expansion, international direct sales initiatives, and product innovation. Management emphasized the potential for gross margin improvement as the Mobi platform scales and pharmacy distribution broadens, but acknowledged that near-term U.S. growth will be moderate given commercial transformation efforts and heightened competition. CFO Leigh Vosseller highlighted the importance of achieving operational efficiencies to support profitability, cautioning that, “these new systems and sales teams are just not completely implemented yet.” The company’s focus remains on driving adoption across both type 1 and type 2 diabetes markets, with an eye on reaching its $1 billion worldwide sales target for the year.

Key Insights from Management’s Remarks

Management attributed revenue growth to higher pump renewals, expanding pharmacy access, and international market traction, while margin pressures stemmed from ongoing investments and competitive intensity.

• Renewals and MDI conversions: U.S. pump shipments increased, with renewals accounting for just over half of shipments and conversions from multiple daily injections (MDI) making up about two-thirds of new pump starts. This underscores strong customer retention and continued success in attracting new users transitioning from traditional insulin therapy methods.
• Pharmacy channel expansion: Entry into the pharmacy channel is lowering patient out-of-pocket costs and driving incremental sales. Management noted early evidence of improved affordability and access for patients, with approximately 30% of U.S. patient lives now under pharmacy benefit coverage. This initiative is viewed as a lever for both volume growth and margin enhancement.
• International performance and transition: Record international sales were supported by pump demand and supply renewals, even as the company prepares to shift from distributor-led to direct sales operations in select countries. Management sees this move as critical for deepening market relationships and improving margins.
• Product portfolio momentum: The Tandem Mobi platform showed increased adoption, particularly as new features like Android control are slated for release. The t:slim X2 pump’s integration with Abbott’s FreeStyle Libre 3 Plus sensor is in early access, with full U.S. launch planned for the coming months.
• Competitive and operational headwinds: Management cited ongoing business system upgrades and a new market entrant’s expanded sales force as factors delaying the realization of commercial transformation benefits in the U.S., leading to more moderate domestic growth projections.

Drivers of Future Performance

Management expects future performance to be driven by channel expansion, product innovation, and operational efficiency, while acknowledging ongoing competitive and margin headwinds.

• Pharmacy channel and product expansion: The rollout of t:slim supplies through pharmacy channels and increased adoption of the Mobi platform are expected to drive both sales and gross margin improvements. Management believes pharmacy access can accelerate volume growth, broaden patient reach, and eventually support higher profitability as coverage expands beyond the current 30% of the U.S. market.
• International direct sales transition: Moving to direct sales outside the U.S. is anticipated to strengthen customer relationships, support higher prices, and improve recurring revenue streams through pump renewals. Management forecasts a reduced headwind from distributor destocking and expects international operations to contribute a larger share of overall growth.
• Competitive landscape and operational changes: The entry of new competitors and ongoing sales force and system upgrades in the U.S. present risks to near-term growth and margin expansion. Management is focused on completing these changes while maintaining leadership in pump starts and investing in R&D for new features and indications, particularly for the underpenetrated type 2 diabetes market.

Catalysts in Upcoming Quarters

In future quarters, the StockStory team will be closely monitoring (1) the pace of pharmacy channel adoption and the rollout of t:slim supplies, (2) the impact of direct sales transitions and pump renewals in international markets, and (3) the effectiveness of commercial system upgrades and sales force expansion in the U.S. Progress on product launches, especially the Mobi platform and Libre 3 sensor integration, will also be key for assessing execution.

Tandem Diabetes currently trades at $10.52, down from $14.45 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.